Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

Zuberbier, Torsten; Ensina, Luis Felipe; Giménez Arnau, Anna Maria; Grattan, Clive; Kocatürk, Emek; Kulthanan, Kanokvalai; Kolkhir, Pavel

doi:http://dx.doi.org/10.1016/S0140-6736(24)00852-3

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

Llicència

Citació

Zuberbier T, Ensina LF, Giménez-Arnau A, Grattan C, Kocatürk E, Kulthanan K, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024 Jul 27;404(10450):393-404. DOI: 10.1016/S0140-6736(24)00852-3

Resum

Chronic urticaria is a common and debilitating mast cell-driven skin disease presenting with itchy wheals, angio-oedema, or both. Chronic urticaria is classified as spontaneous (without definite triggers) and inducible (with definite and subtype-specific triggers; eg, cold or pressure). Current management guidelines recommend step-up administration of second-generation H1-antihistamines to four-fold the approved dose, followed by omalizumab and ciclosporin. However, in many patients, chronic urticaria does not respond to this linear approach due to heterogeneous underlying mechanisms. A personalised endotype-based approach is emerging based on the identification of autoantibodies and other drivers of urticaria pathogenesis. Over the past decade, clinical trials have presented promising options for targeted treatment of chronic urticaria with the potential for disease modification, including Bruton's tyrosine kinase inhibitors, anti-cytokine therapies, and mast cell depletion. This Therapeutics article focuses on the evidence for these novel drugs and their role in addressing an unmet need for personalised management of patients with chronic urticaria.